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The nature of certain clinical samples (tissue biopsies, ﬂuids) or the
subjects themselves (pediatric subjects, neonates) often constrain the
number of cells available to evaluate the breadth of functional T-cell
responses to infections or therapeutic interventions. The methods
most commonly used to assess this functional diversity ex vivo and to
recover speciﬁc cells to expand in vitro usually require more than 106
cells. Here we present a process to identify antigen-speciﬁc responses
efﬁciently ex vivo from 104–105 single cells from blood or mucosal
tissues using dense arrays of subnanoliter wells. The approach com-
bines on-chip imaging cytometry with a technique for capturing
secreted proteins—called “microengraving”—to enumerate antigen-
speciﬁc responses by single T cells in amanner comparable to conven-
tional assays suchas ELISpot and intracellular cytokine staining.Unlike
those assays, however, the individual cells identiﬁed can be recovered
readily bymicromanipulation for further characterization in vitro. Ap-
plying this method to assess HIV-speciﬁc T-cell responses demon-
strates that it is possible to establish clonal CD8+ T-cell lines that
represent the most abundant speciﬁcities present in circulation using
100- to 1,000-fold fewer cells than traditional approaches require and
without extensive genotypic analysis a priori. This rapid (<24 h), efﬁ-
cient, and inexpensive process should improve the comparative study
ofhumanT-cell immunologyacrossagesandanatomic compartments.
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CD8
+ T cells are a critical component of the adaptive immune
system and provide immunological surveillance in peripheral
tissues. Clonal variants use unique T-cell receptors (TCRs) to
recognize intracellular pathogens or malignantly transformed
cells through cognate interactions with disease-speciﬁc peptides
presented in class I major histocompatibility complexes (pMHC)
on the surface of potential targets. The repertoire of human
CD8+ T cells within an individual is estimated to consist of ∼106–
108 different speciﬁcities (1). However, only a fraction of these
clonal variants recognize and respond to any particular antigen.
For example, in chronic HIV infection, HIVGag-speciﬁc CD8+ T
cells comprise 0.2–9% of all circulating CD8+ T cells, but in most
instances their abundance is less than 2% (2). Characterizing the
breadth of epitopes recognized by antigen-speciﬁc CD8+ T cells,
even ones that represent subdominant populations, is important
for understanding immune-mediated control of intracellular
infections and for designing and evaluating clinical interventions
such as vaccines.
Determining both the breadth of the antigen-speciﬁc T-cell re-
sponse (the range of unique epitopes targeted) and the nature of
their functional responses (cytokine secretion, ability to inhibit viral
replication, and other functions) is a challenging task. In some
cases, the diversity of T-cell epitopes is small: For example, T-cell
responses to melanoma usually are well deﬁned (e.g., HLA*A02-
restricted MART-1) (3). However, variations in genotypes among
the population broaden the immunodominant epitopes induced by
most natural infections or by vaccines. The breadth of the CD8+ T-
cell response routinely is determined by ELISpot, using ﬁrst pools
of peptides and then individual peptides to conﬁrm speciﬁcities (4).
Such analysis requires substantial numbers of cells (∼106–107) and
typically measures only a single functional response (secretion of
IFN-γ). Signiﬁcantly, cells identiﬁed in these assays cannot be re-
trieved, and secondary procedures are needed to establish clonal
lines with which other biologically relevant functions, such as the
ability to inhibit viral replication, can be determined.
The isolation of antigen-speciﬁc CD8+ T cells now is commonly
performed ex vivo by ﬂow-cytometric sorting using ﬂuorescently
labeled recombinantmultimers ofHLA–peptide complexes to label
cells of interest (5). This processminimally requires determining the
haplotype of HLAs for a subject. Additionally, the dominant epit-
opes usually are veriﬁed by ELISpot to focus the subsequent anal-
ysis with multimeric reagents, which are expensive to produce
recombinantly (∼$1,000 or more for each one) and have limited
varieties of HLA types/epitopes available. Exchanging peptides in
the pMHC complexes and using combinatorial sets of labels have
improved the scalability and sensitivity of this approach to charac-
terize deﬁned subsets of rare antigen-speciﬁc T cells (6, 7), although
serial screens for each epitope of interest often are necessary and
therefore increase the number of cells required. In aggregate, the
total process has a remarkably poor yield (∼10–100 unique clones
from 106–107 cells per patient), is labor intensive, and is expensive.
Many clinical studies would beneﬁt from alternative strategies
for T-cell cloning that are sample efﬁcient. Quantities of blood
from infant and pediatric subjects often are limited, restricting
detailed analyses of repertoires. Tissue biopsies also typically yield
less than 106 cells, with certain samples, such as cytobrushes or
cerebrospinal ﬂuids, containing only ∼104–105 cells (8, 9). Micro-
scale assays that use microtiter plates or spotted arrays of proteins/
peptides have provided alternative means to enumerate antigen-
speciﬁc T cells from limited numbers of cells but have not enabled
routine cloning of identiﬁed cells (10–12). More efﬁcient processes
for recovering T cells for additional characterization would im-
prove knowledge about the phenotypic and functional diversity of
T-cell responses across anatomical sites and patient populations.
We previously demonstrated that dense, elastomeric arrays of
“nanowells,” microfabricated wells (∼105 per array) with sub-
nanoliter volumes (125 pL), are useful for generating printed
microarrays of cytokines released by polyclonally activated human
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T cells (13). This method—called “microengraving”—is based on
intaglio printing: A glass slide is temporarily sealed to the array of
nanowells to capture analytes secreted by conﬁned cells in both
a multiplexed and quantitative manner. This information can
guide the recovery of T cells for clonal expansion (14). We also
have shown that these arrays of nanowells can enable the con-
current measurement of both cytokine secretion and cytolytic ac-
tivity to monitor ex vivo cytotoxic T lymphocytes (CTLs) (15).
Here we describe and validate a bioanalytical process that
integrates data from both microengraving and on-chip cytometry
to identify and recover antigen-speciﬁc CD8+ T cells ex vivo
from human subjects on the basis of the cytokines secreted fol-
lowing antigen-dependent activation. We demonstrate that the
process enumerates cells activated by antigen akin to conven-
tional methods such as ELISpot and intracellular staining (ICS)
and allows the detection of HIV-speciﬁc CD8+ T cells across
a wide range of epitope speciﬁcities using samples of limited size
(∼104–105 cells) from blood or tissue. The identiﬁed T cells can
be retrieved and expanded in vitro for subsequent mapping of
ﬁne speciﬁcities and detailed functional characterization. The
results indicate that this process is highly efﬁcient, with a 100- to
1,000-fold reduction in cells required ex vivo, and should facili-
tate detailed clonotypic analyses of CD8+ T cells in many areas
of human immunology where the numbers of cells are in-
trinsically small, including tissue biopsies and pediatric samples.
Results
Design of Integrated Single-Cell Analysis to Detect Antigen-Speciﬁc
CD8+ T-Cells ex Vivo. To establish an efﬁcient method for combined
functional characterization ex vivo (cytokine secretion) and
in vitro (epitope mapping and inhibition of viral replication), we
designed a bioanalytical process to characterize and retrieve an-
tigen-speciﬁc CD8+ T cells that also minimizes the total number
of cells interrogated. The approach uses an array of nanowells to
isolate mononuclear cells after incubation with overlapping pools
of peptides (OLPs) or whole antigen (Fig. 1A). The array con-
taining cells then is used for multiplexed microengraving to
identify antigen-dependent activation of CD8+ T cells. Because
analysis by microengraving maintains cell viability, the array of
cells can be imaged to enumerate viable CD8+ T cells, and anti-
gen-speciﬁc CD8+ T cells can be retrieved by micromanipulation.
Validation of Process for Enumerating T Cells Activated ex Vivo. We
ﬁrst tested the ability of our integrated process to determine
multifunctional proﬁles for CD8+ T cells activated ex vivo in
a polyclonal manner. Previously frozen peripheral blood mono-
nuclear cells (PBMCs) were thawed and then stimulated for 5 h
with Staphylococcal enterotoxin B (SEB), a superantigen that
stimulates T cells in a Vβ-speciﬁc manner. Using unsorted PBMCs
minimizes manipulations and allows T cells to average over het-
erogeneities among antigen-presenting cells (APCs). It also obvi-
ates the need for haplotyping a priori to determine suitable HLA-
matched APCs. An aliquot of ∼200,000 cells in 300 μL then was
transferred to the array of nanowells and allowed to settle via
gravity for 10 min. The array of cells was rinsed with serum-free
medium, placed in contact with a glass slide coated with capture
antibodies speciﬁc for cytokines commonly associated with CD8+
cytotoxic T-cell responses (TNF, IFN-γ and IL-2), and incubated
for 2 h at 37 C. After incubation, the glass slide was separated
from the array of nanowells, washed, and stained with ﬂuorescent
antibodies to detect captured cytokines. The cells then were la-
beled in situ with a viability dye (Calcein AM) and with a ﬂuo-
rescently labeled antibody against CD8. Wells containing single
live CD8+ cells were identiﬁed by imaging cytometry (Fig. S1) and
were matched to the data from those wells corresponding to the
cytokines captured by microengraving (Fig. 1B). Each experiment/
array therefore generated a composite dataset that typically
comprised phenotypic proﬁles for 10,000–30,000 individual live
CD8+ cells within a mixed population of mononuclear cells.
We next evaluated our process with clinical samples from
subjects chronically infected with HIV-1. There is substantial
evidence that HIV-speciﬁc CD8+ T-cell responses are essential
to the containment of infection in vivo (16). The induction of
HIV-speciﬁc CTLs is temporally associated with a decline in
plasma viremia following acute infection (17, 18), and there are
strong correlations between protection from progressive HIV
infection and certain HLA class I alleles such as HLA B57, B51,
and B27 (19, 20). ELISpot, ICS, and bulk cytolytic assays have
shown that HIV-speciﬁc CD8+ T cells can produce Tc1-associ-
ated cytokines such as IFN-γ, TNF, and IL-2 and eliminate target
cells by direct cytolysis upon TCR-mediated recognition of their
cognate antigen (21, 22).
We selected a group of HIV+ subjects with varying viral loads
(<50–106,000 RNA copies/mL) (Table S1). These subjects in-
cluded individuals with spontaneously controlled HIV infection
in the absence of antiretroviral therapy (“HIV controllers”),
those with progressive infection who were not receiving anti-
retroviral therapy (“chronic progressors”), and individuals re-
ceiving anti-HIV drug therapy (“chronic treated”). We ﬁrst
conﬁrmed that these individuals exhibited a range of frequencies
of IFN-γ–producing CD8+ T cells speciﬁc for the viral protein
Gag by ELISpot assays performed against HLA-matched opti-
mal epitopes. The protein Gag was chosen speciﬁcally because
the breadth, magnitude, and functional capacity of CD8+ T-cell
responses toward Gag have been demonstrated to be a reason-
able predictor of effective anti-HIV immunity (23, 24).
Fig. 1. Characterization of multifunctional analysis of CD8+ T cells by micro-
engraving. (A) Schematic illustration of approach to measure antigen-speciﬁc
responses by T cells using a combination of microengraving and imaging
cytometry to capture secreted cytokines and enumerate CD8+ T cells. (B) Rep-
resentative composite proﬁles of individual activated CD8+ T cells. (C) Pie charts
indicating the relative percentages of T cells secreting one or more cytokines
(IFN-γ, green; TNF, blue; IL-2, red) following stimulationwith SEB. Cells are from
three different HIV+ subjects. Percentages represent the fraction of cells se-
creting cytokine within the population of single T cells examined.
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For three of these subjects, we stimulated PBMCs with SEB for
5 h and proﬁled the breadth of cytokines secreted by micro-
engraving. A subset of individual CD8+ T cells from all three
subjects (1–4%) showed a range of responses, including CD8+ T
cells secreting multiple cytokines simultaneously (Fig. 1C). The
relative distribution of functional responses measured was similar
to those determined by ICS, with the most dominant populations
producing IFN-γ alone, in combination with either TNF or IL-2 or
in combinationwith IL-2 and TNF together (Fig. S2). Unlike IFN-γ
or IL-2, TNF is synthesized initially as a membrane-bound protein
that subsequently is cleaved into a soluble form (25). Therefore
the higher frequency of cells producing TNF identiﬁed by ICS
relative to microengraving [regardless of other cytokines those
cells may express concurrently, (e.g., more IFN-γ+TNF+ pro-
duction by ICS vs. microengraving)], likely results from the si-
multaneous detection of both membrane-bound and secreted
forms (26). Overall, these results indicate that our process using
microengraving to evaluate multifunctional cytokine responses by
activated CD8+ T cells is similar to ICS.
Comparison of Methods for Enumerating Antigen-Dependent CD8+ T
Cells ex Vivo. We next conﬁrmed that our method could detect
the activation of CD8+ T cells in an antigen-dependent manner.
PBMCs from three HIV-positive individuals were thawed and
rested overnight, and their responses were tested against a pool
of 66 OLPs (8–10 amino acids each) encompassing the entire Gag
protein, an irrelevant melanoma-derived peptide (ELAGIGILTV,
EV9) as a negative control, or SEB as a positive control. After
incubation with either peptide or SEB for 5 h, the cells were
distributed onto an array of nanowells that then was used for
microengraving to detect secreted IFN-γ from single, viable
CD8+ cells. The data conﬁrmed the ability of our approach to
detect antigen-dependent responses consistently for both tech-
nical and biological replicates (Fig. 2 A and B); the frequency of
antigen-speciﬁc responses ranged from 0.06–0.3%. Using the
frequencies of IFN-γ responses measured with the irrelevant
peptide, we estimate that the lowest limit of detection possible
for the assay is 0.004%, or 1 in 25,000 wells, roughly the same
order of magnitude as the number of wells scored. This projected
theoretical limit is consistent with a previous estimate we de-
termined for single peptides and antigen-speciﬁc activation of
CD4 T-cell clones (27) and with that reported for another cell-
based microarray for enumerating T cells (12).
We next quantitatively determined the relationships between
our microengraving-based process and the two most common
techniques used to assess the magnitude of HIV-speciﬁc CD8+
T-cell responses—ELISpot and ICS/ﬂow cytometry. Because
cells producing IFN-γ were the most abundant population in our
polyclonal comparison with ICS, and ELISpot has been well
qualiﬁed for IFN-γ, we measured the antigen-induced pro-
duction of IFN-γ from PBMCs isolated from 14 HIV+ individ-
uals. We initially characterized the frequencies of CD4 vs. CD8
T cells in the PBMCs of these patients using ﬂow cytometry (Fig.
S3 and Table S1). The frequency of IFN-γ–secreting cells iden-
tiﬁed by microengraving ranged from 0.04–0.26% when scoring
single CD8+ T cells stimulated with a pool of Gag OLPs for 5 h.
These results showed a signiﬁcant correlation with comparable
measures obtained by ICS (P ≤ 0.0001, r = 0.87) (Fig. 2C) and
ELISpot (P = 0.01, r = 0.69) (Fig. S4). Results obtained by ICS
and ELISpot also correlated with each other (P= 0.01, r= 0.90).
Because the microengraving process can accommodate 105 or
fewer cells, we then veriﬁed that our method could quantify the
frequency of HIV Gag-speciﬁc CD8+ T-cell responses from both
the peripheral blood and intestinal mucosal compartments of
two chronically infected subjects (Fig. 2D). These data showed
distinct frequencies of HIV-speciﬁc responses in each region.
Together, these data demonstrate that our microengraving-based
process allows the direct ex vivo enumeration of antigen-speciﬁc
CD8+ T cells from both peripheral and mucosal compartments.
Rapid and Efﬁcient Cloning of HIV-Speciﬁc CD8+ T Cells. Labeling
antigen-speciﬁc T cells with recombinant peptide–MHC com-
plexes is useful for recovering T cells with known speciﬁcities and
relatively high avidities, but it requires a priori knowledge about
the haplotype and frequencies of responses of the individual.
Antigenic stimulation of cells and analysis by ICS allows the
identiﬁcation of antigen-speciﬁc CD8+ T cells ex vivo, but the
method renders the cells nonviable. This outcome precludes
Fig. 2. Validation ofmicroengraving for identifyingHIV-speciﬁc responses. (A)
Bar graph of the frequencies of IFN-γ+ responses scored for CD8+ cells isolated
from three different aliquots of PBMCs from the same HIV+ patient stimulated
with either a pool of peptides (Gag) orwith controlmedium (Mock). Anaverage
of ∼6,000 live CD8+ cells were proﬁled in replicates of each assay. (B) Bar graph
of the frequencies of IFN-γ+ responses scored for CD8+ cells isolated from three
different HIV+ subjects. The measurements included stimulation with an irrele-
vant peptide (melanomaELAGIGILTV,Mel), a pool of 66OLPs fromGag, and SEB.
Anaverageof∼16,000 liveCD8+ cellswere proﬁled in eachassay. (C) Scatterplots
of responses measured from HIV+ subjects by ICS and microengraving. Each di-
amond indicates one subject. The correlations were assessed by Spearman’s
rank correlation. (D) Assessment of frequencies of HIV Gag-speciﬁc CD8+ T-cell
responses in blood and mucosal compartments from two chronically infected
subjects (CTR0278 and 505402) as assessed by microengraving.
Varadarajan et al. PNAS | March 6, 2012 | vol. 109 | no. 10 | 3887
IM
M
U
N
O
LO
G
Y
EN
G
IN
EE
RI
N
G
further analysis of cells of interest to assess their ability to pro-
liferate in vitro, their ability to inhibit viral replication, or their
functional ability to lyse infected cells. Because microengraving is
a nondestructive process, and cells have known spatial addresses
within the array of wells used, we expected that microengraving
would allow the efﬁcient recovery of activated antigen-speciﬁc
cells by micromanipulation for clonal expansion (Fig. S5) (14, 28).
We identiﬁed an HIV controller, CTR0278, who had a de-
tectable Gag-speciﬁc IFN-γ response in the peripheral blood but
whose CD8+ T cells isolated ex vivo, interestingly, failed to re-
duce viral replication of an HIV laboratory strain (JRCSF)
in vitro. To enable a comparison of the breadth and speciﬁcity of
Gag-speciﬁc cells recovered using our microengraving-based
method, we ﬁrst determined the relative breadth of the HIV-
speciﬁc CD8+ T cells by ELISpot (Fig. 3A). The most abundant
Gag-speciﬁc responses were directed toward epitopes contained
within p17 and p24. We then used microengraving to identify and
recover CD8+ T cells secreting IFN-γ from this subject. PBMCs
were incubated with pooled OLPs from Gag for 5 h, and the
proﬁles for cytokine secretion were measured using micro-
engraving. In one representative experiment, cells that secreted
IFN-γ were enumerated (33 positive events out of 9,925 live
CD8+ T cells, 0.33%), and their addresses were determined for
subsequent recovery by automated micromanipulation. Experi-
ments with other donors yielded similar numbers of events.
From three independent experiments, we retrieved IFN-
γ+/CD8+ T cells from 108 wells and then cultivated those single
cells in RPMI with irradiated feeder cells, IL-2, and an anti-CD3
antibody to allow efﬁcient clonal expansion. Of these single cells,
93% (100/108) successfully expanded to generate cell lines
comprising at least 106 cells, sufﬁcient numbers to run in vitro
assays. We then mapped the HIV epitope speciﬁcities for 12 of
these clonal cell lines by ELISpot. Each of these clones elicited
a response to a single Gag OLP or to two adjacent ones con-
tained within the original pool and subsequently also responded
to an HLA-matched optimal peptide contained within the
mapped OLP(s) (Table S2). Although the small number of
characterized clonal cell lines precludes quantitative compar-
isons between frequencies of responses in PBMCs and the clonal
lines established, the clones covered all ﬁve optimal responses
identiﬁed by ELISpot from PBMCs including one (Cw8-RV9)
that was near the lower limit of detection for those assays (∼60
spot-forming units per 106 cells) (Fig. 3B). This result conﬁrms
that the microengraving-based method enumerates a broad
range of responses and suggests that extended depth of analysis
or expanded recovery may identify other clonotypic variants
below the limit of detection of ELISpot.
The clonal lines also were tested to determine their capacity to
inhibit viral replication in vitro (Fig. 4). Although the complete
pool of CD8+ T cells isolated ex vivo failed to inhibit viral repli-
cation, individual isolated clonal lines showed varying degrees of
viral inhibition. A clone speciﬁc for HLA-A2-FK10 was unable to
inhibit viral replication, despite induction of IFN-γ by the cognate
peptide in ELISpot assays, whereas a clone speciﬁc for HLA-A2-
SL9 exhibited a 3-log reduction in a p24 ELISA-based viral-in-
hibition assay. Clones with speciﬁcities against HLA-B14-DA9
and against HLA-Cw8-RV9 showed intermediate levels of in-
hibition. Thus, although bulk CD8+ T cells failed to inhibit viral
replication signiﬁcantly, lines with single epitope speciﬁcities de-
rived from the bulk population showed signiﬁcant antiviral activity,
further underscoring the importance of broadly proﬁling the di-
versity of T-cell responses from patients.
Discussion
We have demonstrated a rapid, inexpensive, and efﬁcient process
for combining ex vivo and in vitro functional characterization of
HIV-speciﬁc CD8+ T cells. The time required for executing the
process and isolating cells on the basis of phenotype is less than 24 h.
The cost per assay is comparable to that for performing a single 96-
well plate ELISpot, and the assay can accommodate small samples
(10,000–100,000 cells or fewer) easily. The microengraving-based
method used has a sensitivity and speciﬁcity similar to ELISpot for
evaluating antigen-speciﬁc responsiveness but also measures mul-
tifunctional responses without rendering cells nonviable.
The enumeration of IFN-γ+ CD8 T cells following antigenic
stimulation as determined by microengraving correlated well with
responses determined by both ICS andELISpot. Themagnitude of
the responses, however, was more similar to that measured by
ELISpot; ICS estimated approximately 10-fold more events. Both
ELISpot and microengraving measure proteins secreted in
a paracrine manner by viable cells, whereas ICS measures total
protein synthesized by rendering cells nonviable. Indeed, previous
reports comparing the magnitude of virus-speciﬁc responses (to
HIV/cytomegalovirus/simian immunodeﬁciency virus) measured
Fig. 3. Dominant epitopes recognized by CD8+ T cells from
an elite controller. (A) Rank-ordered bar graph of the most
frequent responses measured by ELISpot, and organized by
epitope, among CD8+ T cells from elite controller CTR0278 run
in triplicate. Filled bars indicate Gag-speciﬁc responses. (B) Bar
graph of the frequencies of T-cell clones recognizing speciﬁc
epitopes in gag identiﬁed by microengraving and recovered
by micromanipulation. SFU, spot-forming units.
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by ELISpot and ICS in both humans and macaques have demon-
strated that themagnitude of responses determined via ELISpot is
consistently lower than that of responses determined via ICS—
ﬁndings that agree with those observed here for both ELISpot and
microengraving (29–31). The limited window of measurement
afforded in microengraving relative to integrated ICS also may
affect the lower number of events enumerated (32).
The ability to recover and expand by microengraving individual
identiﬁed HIV-speciﬁc cells that may have functional signiﬁcance
in vivo despite poor detection in bulk assays should help reﬁne our
understanding of effective T-cell–mediated immune responses in
one or more anatomical compartments (33). HIV-speciﬁc CD8+ T
cells are important for the control of viremia, but the critical
functions performed by these cells that contribute to control remain
unknown (34, 35).More complex functions, such as proliferation or
simultaneous expression of multiple cytokines, may better identify
effective CD8+ cytotoxic T lymphocytes (36, 37). The ability of
CTLs to recognize and kill virus-infected cells may be critical for
mediating control in vivo, and it may be crucial to evaluate these
functions comprehensively in vitro (38). We show that functional
characterization of individual clones by in vitro viral-inhibition
assays can identify functionality linked to single epitopes not
detected by similar bulk assays. It also should allow a straightfor-
ward approach to investigate the role of TCRuse in functional CTL
activity based on the TCR sequences of identiﬁed clones.
One signiﬁcant advantage afforded by the enhanced efﬁciency of
the microengraving-based approach for recovering antigen-speciﬁc
T cells should be its application in monitoring responses when
clinical samples simply have sparse numbers of cells, such as
mucosal tissues, pediatric blood samples, or genital secretions.
The microengraving-based approach also allows a less biased
assessment of immune targeting than other currently available
approaches. It does not require a priori knowledge of haplotypes
and accommodates diverse sources of antigen, including whole
proteins or even pathogens. In this way, broad coverage of the T-
cell response can be assessed in an initial screen. The method shifts
the burden of establishing epitope speciﬁcity to the expanded
clones, but for small samples, detailed analysis to determine spec-
iﬁcity may be determined more effectively when more cells are
available after expansion. In our screen of the T-cell response from
an HIV controller, we recovered representative clones for each of
the most abundant speciﬁcities determined by ELISpot from only
a small pool of those generated. Increasing the number of clones
sampled and subsequent analyses of those clones should enable
broad coverage of the T-cell response. The ability to establish
clonal lines also should allow additional characterization, such as
the determination of clonotypes and proliferative capacity (39).
In conclusion, this bioanalytical process establishes a rapid and
efﬁcient approach for cloning primary antigen-speciﬁc T cells and
will provide opportunities to characterize HIV-speciﬁc responses,
among others. In particular, we expect that it will be useful when
the number of cells available is insufﬁcient for extensive analysis
by standard techniques or when it is critical to assess antigenic
coverage broadly with minimal bias. The application of this
technique should inform studies of HIV pathogenesis as well as
aid the assessment of potential HIV vaccine candidates and has
broad relevance to other areas of immunology.
Materials and Methods
Patient Samples. HIV-infected individuals were enrolled at Massachusetts
General Hospital in accordance with institutional review board-approved
protocols. PBMCs were isolated from blood by Ficoll (Sigma) density puriﬁ-
cation in accordance with the manufacturer’s instructions. Fresh or frozen
PBMCs were used subsequently for the described experiments. Mucosal bi-
opsies from the small bowel and colon were obtained by endoscopy, and
a matching blood sample was obtained the same day. Biopsy samples were
disaggregated with collagenase, as described previously (40).
Fabrication of Nanowell Arrays. Arrays of 1-mm-thick polydimethylsiloxane
nanowells (50 μm) were manufactured by replica molding using a custom-
built mold, adhered directly to a 3 in ×1 in glass slide, and sterilized in an
oxygen plasma before use (41).
Activation and Deposition of Cells. Experiments were performed with frozen
PBMCs that were thawed and rested overnight (12–16 h) or with fresh
mononuclear cells from blood and intestinal biopsies. An aliquot of 1 × 106
cells in 500 μL of R10 (RPMI + 10% FBS) was stimulated with SEB or with a pool
of 66 OLPs (8–10 amino acids each; 2 μg/mL) encompassing the entire Gag
protein (or ELAGIGILTV as a control) along with the costimulatory antibodies
Fig. 4. In vitro viral-inhibition assays. Representative results from each of the ﬁve different epitopes identiﬁed via microengraving and the bulk CD8+ T cells
from sample CTR0278, showing inhibition of viral replication over 7 d of culture. Open circles represent autologous activated CD4+ T cells infected with HIV-1
strain JRCSF; closed diamonds represent CD4/CD8 cocultures; open triangles represent CD4+ T cells without superinfection with HIV-1 strain JRCSF. Each
experiment was run in triplicate. Error bars represent SD.
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anti-CD28 and anti-CD49d for 5 h. Stimulated cells were counted and adjusted
to a density of 1× 106 cells/mLA 300-μL aliquot of the cells was deposited onto
a sterilized array of nanowells. The cells settled via sedimentation for 10 min
and were then examined by microscopy to estimate the frequency of loading
(approximately one cell per well). Excess cells were removed by rinsing the
array gently with medium and subsequent aspiration.
Microengraving and On-Chip Cytometry. The cell-loaded array was washed
with serum-free medium containing 5 ng/mL of IgG (to facilitate registration
of the nanowell array to the printed microarray). A polylysine-functionalized
glass was preincubated for 1 h with capture antibodies against IFN-γ, TNF-α,
IL-2, and Ig (25 μg/mL each). The slide was blocked with 3% milk/PBS-Tween
(0.05%, PBST), washed twice with PBST, and dried. The nanowell array was
held in contact with the glass slide under compression in a hybridization
chamber (Agilent) and incubated (37 8C, 5% CO2) for 2 h. After incubation,
the glass slide was separated from the nanowell array, washed, and labeled
with the appropriate ﬂuorescent antibodies, as described previously (41).
The printed microarrays were imaged using a Genepix 4200AL (MDS Corp.).
The array of cells subsequently was labeled in situ with Calcein violet live cell
marker (1 μM; Invitrogen) and a ﬂuorescent antibody against CD8 (5μg/mL
each) and then was incubated in the dark for 30 min. The array was imaged
by epiﬂuorescence on an automated microscope (Zeiss). The data from
microengraving and the on-chip cytometry were matched on a per-well basis
for individual viable CD8 cells.
Retrieval and Expansion of T Cells. CD8+IFN-γ+ T cells were retrieved using an
automated micromanipulator (CellCelector; AVISO GmbH) (28). Retrieved
cells were incubated in a well of a 96-well plate with 200 μL of R10 sup-
plemented with 100 U/mL of IL-2 (R10/100) containing irradiated (2,500 cGy)
HLA-mismatched PBMCs (106/mL) from an HIV− donor (42). Cells were
stimulated with anti-CD3 antibody (clone 12F6), and irradiated feeder cells
were added every 2 wk over the course of approximately 2 mo. During this
time, cells were expanded to larger volumes until there were sufﬁcient cells
available for functional assays (at least 106 cells).
Additional Methods.Additional descriptions ofmethods, including fabrication
of nanowells, functionalization of glass, intracellular staining, ELISpot, and
viral-inhibition assays, are available in SI Materials and Methods.
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